News
Luspatercept appears safe, effective in β-thalassemia
- Author:
- Jen Smith
MADRID—Results of a phase 2 study have shown that luspatercept can produce sustained increases in hemoglobin and reductions in transfusion burden...
News
Nivolumab for long-term treatment of cHL after auto-HSCT
- Author:
- Jen Smith
LUGANO, SWITZERLAND—Nivolumab can provide long-term treatment for a broad range of adults who have relapsed or refractory classical Hodgkin...
News
Oral combo produces deep, durable responses in MM
- Author:
- Jen Smith
An all-oral treatment regimen can produce deep and durable responses in patients with newly diagnosed multiple myeloma (MM), according to a...
News
CAR T-cell therapy shows early promise in DLBCL
- Author:
- Jen Smith
LUGANO, SWITZERLAND—The chimeric antigen receptor (CAR) T-cell therapy JCAR017 can produce “potent and durable” responses in patients with...
News
T-cell product improves outcomes of haplo-HSCT
- Author:
- Jen Smith
MADRID—Updated results of a phase 1/2 study suggest the T-cell product BPX-501 lowers the risks associated with haploidentical hematopoietic stem...
News
Less is more in PET-negative, advanced HL
- Author:
- Jen Smith
MADRID—Patients with advanced Hodgkin lymphoma (HL) who are PET-negative after initial treatment with 2 cycles of eBEACOPP* should only receive 2...
News
Chemo-free triplet produces ‘favorable’ results in advanced disease
- Author:
- Jen Smith
LUGANO, SWITZERLAND—A chemotherapy-free combination regimen has demonstrated “favorable” safety and efficacy in patients with advanced chronic...
News
Inhibitor elicits responses in heavily pretreated FL, DLBCL
- Author:
- Jen Smith
LUGANO, SWITZERLAND—Interim results of a phase 2 trial suggest tazemetostat can be effective in patients with heavily pretreated, relapsed or...
News
MRD predicts outcome of HSCT in ALL, study suggests
- Author:
- Jen Smith
ORLANDO, FL—Minimal residual disease (MRD) measurements before and after hematopoietic stem cell transplant (HSCT) can help predict outcomes in...
News
Combo prevents GVHD, prolongs survival in monkeys
- Author:
- Jen Smith
ORLANDO, FL—A 2-drug combination is “an exceptional candidate for clinical translation” as prophylaxis for graft-vs-host disease (GVHD), according...
News
Drug produces high response rates in AITL
- Author:
- Jen Smith
Photo by Larry Young SAN FRANCISCO—Treatment with 5-azacitidine (5-AZA) can produce a high response rate in patients with relapsed/refractory...
News
OS is worse with refractory vs relapsed PTCL
- Author:
- Jen Smith
Photo by Larry Young SAN FRANCISCO—Patients with refractory peripheral T-cell lymphoma (PTCL) have significantly worse overall survival (OS) than...
News
Regimens seem similarly effective in ENKTL
- Author:
- Jen Smith
SAN FRANCISCO—Interim results of a phase 3 trial suggest 2 treatment regimens may provide comparable efficacy in patients with extranodal natural...
News
Project provides insight into T-cell lymphoma
- Author:
- Jen Smith
SAN FRANCISCO—The T-Cell Project has provided information that can enhance our understanding of T-cell lymphomas, according to a presentation at...
News
Group proposes new prognostic model for PTCL-NOS
- Author:
- Jen Smith
T-cell Lymphoma Forum Photo by Larry Young SAN FRANCISCO—Researchers have used data from the T-Cell Project (TCP) to create a prognostic model...